In This Article:
As global markets experience volatility amid renewed tariff threats and fluctuating economic indicators, Asian stock markets are also navigating these challenging conditions. In such an environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Pansoft (SZSE:300996) | CN¥14.27 | CN¥28.25 | 49.5% |
| Livero (TSE:9245) | ¥1694.00 | ¥3383.28 | 49.9% |
| Range Intelligent Computing Technology Group (SZSE:300442) | CN¥43.44 | CN¥85.01 | 48.9% |
| Devsisters (KOSDAQ:A194480) | ₩38100.00 | ₩76151.09 | 50% |
| Zhuhai CosMX Battery (SHSE:688772) | CN¥13.46 | CN¥26.77 | 49.7% |
| Kolmar Korea (KOSE:A161890) | ₩84600.00 | ₩168491.07 | 49.8% |
| Kanto Denka Kogyo (TSE:4047) | ¥832.00 | ¥1644.44 | 49.4% |
| KG Mobilians (KOSDAQ:A046440) | ₩4255.00 | ₩8288.55 | 48.7% |
| SpiderPlus (TSE:4192) | ¥460.00 | ¥919.15 | 50% |
| Cosmax (KOSE:A192820) | ₩209500.00 | ₩407469.70 | 48.6% |
Here's a peek at a few of the choices from the screener.
LigaChem Biosciences
Overview: LigaChem Biosciences Inc. is a clinical stage biopharmaceutical company focused on discovering and developing medicines for unmet medical needs, with a market cap of ₩4 trillion.
Operations: The company generates revenue from two main segments: Pharmaceutical Business, contributing ₩20.54 billion, and New Drug Research and Development, accounting for ₩105.36 billion.
Estimated Discount To Fair Value: 33.3%
LigaChem Biosciences is trading at ₩110,400, considerably below its estimated fair value of ₩165,629.14. Despite recent negative sales figures, the company turned profitable with a net income of KRW 7.8 billion in 2024 and forecasts significant earnings growth of 58.9% annually over three years. The strategic alliance with WuXi XDC enhances ADC development capabilities, potentially boosting cash flows further as LigaChem capitalizes on this partnership for innovative therapies.
RemeGen
Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$31.70 billion.
Operations: RemeGen's revenue is primarily derived from its biopharmaceutical research, service, production, and sales segment, totaling CN¥1.91 billion.